Published date: 6 October 2023
Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.
Contract summary
Industry
Diagnostics and radiodiagnostic devices and supplies - 33124000
Diagnostic systems - 33124110
Diagnostic kits - 33141625
Blood-testing reagents - 33696200
Laboratory reagents - 33696500
Automation system - 48921000
Laboratory services - 71900000
Location of contract
BS34 7QH
Value of contract
£50,000,000
Procurement reference
CF-1919200D0O000000rwimUAA
Published date
6 October 2023
Closing date
7 December 2023
Closing time
6pm
Contract start date
29 July 2024
Contract end date
30 July 2034
Contract type
Service contract
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below.
All in vitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked. The intended use of the assays must include use on human blood, stem cell, and tissue donors.
Great Britain (GB) will continue to recognise CE marking under the IVDD or IVDR until devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT system (PULSE) without the need for changes to PULSE. NHSBT are looking for a fully integrated, high throughput, automated Nucleic Acid Testing (NAT) screening system which can detect HCV RNA, HIV-1 RNA, HIV-2 RNA, HBV DNA, HEV RNA, and WNV RNA.
NAT Screening will be performed by NHSBTs two testing sites in England at Manchester and Bristol (Filton). Samples from blood donors donations will be pooled prior to screening therefore pooling equipment is also required as part of the solution. Samples from stem cell and living tissue donors will be screened as individual donations and therefore not pooled.
Throughput requirements:
HCV RNA, HIV-1 RNA, HIV-2 RNA, HBV DNA, HEV RNA: 1,520,000 samples per year
WNV RNA: 48,000 samples per year
At a minimum, HCV, HIV, and HBV must be multiplexed
KEG approval is a mandatory requirement for this opportunity, in-line with the requirements of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book).NHSBT will seek to understand the status of assays which would be offered with regards to KEG within the Tender.
More information
Additional text
-
To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome.
Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at:
Phone: 0800 9956035
E-mail: support-health@atamis.co.uk
About the buyer
Contact name
Tennille Madigan
Address
Bristol
Bristol
BS34 7QH
United Kingdom
Telephone
+447795483583
Share this notice
Closing: 7 December 2023, 6pm
All content is available under the
